Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Clin Cancer Res. 2019 Nov 6;26(1):71–81. doi: 10.1158/1078-0432.CCR-19-2078

Figure 1. Second line treatment of pancreatic cancer with pelareorep, pembrolizumab, and chemotherapy results in disease control in 50% of the six efficacy-evaluable patients.

Figure 1.

(A) Overview of study schedule indicating scheduled tumor biopsies [BX] and blood draw for correlative studies [CS]. (B) Swimmers plot of survival time of patients on study. (C) Spider plot of tumor response based on the sum maximum diameter changes in target lesions.